Beijing, China

Xiangyu Zhao

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Beijing Easpring Material Technology Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiangyu Zhao. Retrieved from https://idiyas.com/inventor/xiangyu-zhao-p8y2p7rd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiangyu Zhao: Innovator in Cathode Materials and Immunotherapy

Introduction

Xiangyu Zhao is a prominent inventor based in Beijing, China. She has made significant contributions to the fields of battery technology and immunotherapy. Although she currently holds no granted patents, her innovative work is reflected in her latest patent applications.

Latest Patent Applications

Xiangyu Zhao's recent patent applications include the following:

1. **Single Crystal Multi-Element Cathode Material, Preparation Method of the Same, and Lithium-Ion Battery** - This application provides a single crystal multi-element cathode material, along with a preparation method and a lithium-ion battery. The multi-element cathode material consists of quasi single crystal particles, each made up of multiple crystal grains. Element G is present at the grain boundaries between these crystal grains, with its concentration decreasing as the distance from the grain boundary to the surface of the quasi single crystal particles increases. Element G can be selected from a range of materials, including Ni, Co, Mn, Ta, Cr, Mo, W, La, Al, Y, Ti, Zr, V, Nb, Ce, Er, and B.

2. **Use of CD90+ Human Amniotic Epithelial Cells in Treatment of Graft Versus Host Disease** - This application outlines a method for treating individuals suffering from graft versus host disease (GvHD) or those at risk of developing it. The method involves selecting a CD90hAEC cell population with enhanced immunoregulation capabilities as a primary therapeutic cell. Research indicates that the stem cell pluripotent markers SSEA4, OCT4, and NANOG in CD90hAECs are significantly higher than in general hAECs, providing better immunomodulatory functions and leading to improved clinical outcomes.

Conclusion

Xiangyu Zhao's innovative work in cathode materials and immunotherapy showcases her potential to impact these fields significantly. Her latest patent applications reflect her commitment to advancing technology and improving therapeutic methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…